Fresenius Kabi Forms a Joint Venture in Collaboration with Bio-Techne and Wilson Wolf to Advance Cell and Gene Therapies

 Fresenius Kabi Forms a Joint Venture in Collaboration with Bio-Techne and Wilson Wolf to Advance Cell and Gene Therapies

Fresenius Kabi Forms a Joint Venture in Collaboration with Bio-Techne and Wilson Wolf to Advance Cell and Gene Therapies

Shots:

  • The JV leverages the expertise of three companies that includes Wilson Wolf’s G-Rex technology, BioTechne’s proteins, reagents, media, and gene-editing technologies and Fresenius Kabi’s Lovo cell processing system washes, concentrates and harvests cells
  • The JV focus on providing scalable manufacturing technologies and processes required to develop and commercialize new cell and gene therapies. All the three partners equally owned the JV
  • Wilson’s G-Rex technology is designed as a scalable and practical platform for the generation of personalized cell therapies, Biotechne’s technology used to activate, reprogram, and stimulate cell growth while Fresenius Kabi’s Lovo cell processing system required to develop and commercialize cell and gene therapies

Click here ­to­ read full press release/ article | Ref: Wilson wolf | Image: Pro Expo

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post